Financial Performance - The company's revenue for Q1 2022 was ¥37,272,422.06, representing a 14.63% increase compared to ¥32,515,128.53 in the same period last year[4] - Net profit attributable to shareholders decreased by 31.07% to ¥7,165,807.56 from ¥10,395,879.49 year-on-year[4] - The net profit after deducting non-recurring gains and losses fell by 43.84% to ¥4,315,963.53 compared to ¥7,684,495.43 in the previous year[4] - Basic and diluted earnings per share decreased by 47.62% to ¥0.11 from ¥0.21 year-on-year[6] - Net profit for the current period was ¥7,156,332.03, a decrease from ¥10,388,539.49, reflecting a decline of approximately 30%[31] - Earnings per share (EPS) for the current period was ¥0.11, down from ¥0.21 in the previous period, showing a decrease of about 47.6%[32] Cash Flow and Assets - The net cash flow from operating activities was negative at -¥2,353,328.55, a decline of 139.60% from ¥5,942,226.22 in the same period last year[4] - Cash inflow from investment activities was ¥294,610,819.98, compared to ¥210,867,036.80 in the previous period, marking an increase of approximately 39.7%[36] - The company's cash and cash equivalents at the end of the period were CNY 8,351,208.16, a decrease from CNY 10,351,875.86 at the beginning of the year, representing a decline of about 19.3%[21] - The net increase in cash and cash equivalents was -2,000,667.70, a significant decline from 4,616,112.41 in the previous period[38] Expenses - Research and development expenses rose by 56.80% to ¥5,619,822.65, driven by increased project costs[11] - The company reported a 55.58% increase in sales expenses, totaling ¥13,081,301.03, primarily due to higher business promotion costs[11] - Total operating costs amounted to ¥32,254,453.36, up from ¥23,426,120.45, indicating a rise of about 37.5%[29] Shareholder Information - Total number of common shareholders at the end of the reporting period is 7,067[14] - The top two shareholders, Yuan Yuyu and Xu Tao, each hold 16.53% of the shares, totaling 10,922,547 shares[14] - The company has a total of 4,508,796 shares held by Yuan Meifu, representing 6.82% of the shares[14] - The company has 4,246,049 shares held by Shenzhen Kaiyingke Technology Co., Ltd., accounting for 6.43% of the shares[14] - The company has a total of 3,267,436 shares held by Guoshou Chengda (Shanghai) Health Industry Equity Investment Center, representing 4.95% of the shares[14] - The top ten shareholders hold a significant portion of the company's shares, with the largest shareholder holding 16.53%[14] Assets and Liabilities - Total assets at the end of Q1 2022 were ¥725,056,387.22, down 2.88% from ¥746,569,716.44 at the end of the previous year[6] - The company reported a total asset of CNY 725,056,387.22 as of March 31, 2022, down from CNY 746,569,716.44 at the beginning of the year, indicating a decrease of approximately 2.3%[25] - The total current assets decreased to CNY 374,706,437.62 from CNY 417,142,182.84, reflecting a reduction of approximately 10.1%[23] - The total liabilities decreased from CNY 170,916,132.74 to CNY 142,246,471.49, reflecting a decline of about 16.9%[25] - The company’s long-term borrowings remained stable at CNY 101,673,625.45, unchanged from the previous period[25] - The company’s equity position is strengthened as total liabilities decreased while total assets also saw a reduction, indicating improved financial stability[25] Investments - Investment income increased by 52.15% to ¥2,179,943.38, attributed to higher financial management returns[11] - The company invested GBP 100,000 in UK-based Reco Medical Ltd, acquiring a 5.01% stake, which aligns with its strategic focus on neurosurgery[19] Certification and Audit - The company has successfully passed the high-tech enterprise certification again, which positively impacts its brand image and market value[18] - The company’s first quarter report was not audited[39]
迈普医学(301033) - 2022 Q1 - 季度财报